The V617F mutation of JAK2 is very uncommon in patients with thrombosis

被引：36

作者：

Remacha, Angel F. ^{[1
]}

Estivill, Camino ^{[1
]}

Pilar Sarda, M. ^{[1
]}

Mateo, Jose ^{[1
]}

Carles Souto, Joan ^{[1
]}

Canals, Carme ^{[1
]}

Nomdedeu, Josep ^{[1
]}

Fontcuberta, Jordi ^{[1
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Dept Hematol, Avda Padre Claret 167, Barcelona 08025, Spain

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 02期

关键词：

JAK2; mutation; idiopathic thrombosis;

D O I：

10.3324/haematol.10358

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Given that many cases of thrombosis do not have a clear cause, a myeloproliferative disease could be involved. We investigated the V617F mutation of the JAK2 gene in 295 patients with thrombosis. Only one case was positive. Therefore, the study of this mutation is not necessary in all patients with idiopathic thrombosis.

引用

页码：285 / 286

页数：2

共 10 条

[1]

ACHARYA J, 1995, EUR J HAEMATOL, V55, P315

[2]

[Anonymous], 2001, Tumours of the Haematopoietic and Lymphoid Tissues

[3] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[4] Budd-Chiari syndrome as the first manifestation of polycythemia vera in young women with inherited thrombophilic state: an aggressive form of myeloproliferative disorder requiring multidisciplinary management [J].

Breccia, M ;

Morano, SG ;

D'Andrea, M ;

Russo, E ;

D'Elia, GM ;

Alimena, G .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 (05) :396-400

[5]

De Stefano V, 1997, SEMIN THROMB HEMOST, V23, P411

[6]

Goerttler PS, 2005, HAEMATOLOGICA, V90, P851

[7] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[8] Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis [J].

McMullin, MF ;

Bareford, D ;

Campbell, P ;

Green, AR ;

Harrison, C ;

Hunt, B ;

Oscier, D ;

Polkey, MI ;

Reilly, JT ;

Rosenthal, E ;

Ryan, K ;

Pearson, TC ;

Wilkins, B .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (02) :174-195

[9] The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism [J].

Tirado, I ;

Mateo, J ;

Soria, JM ;

Oliver, A ;

Martínez-Sánchez, E ;

Vallvé, C ;

Borrell, M ;

Urrutia, T ;

Fontcuberta, J .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (03) :468-474

[10] After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematofogic malignancies [J].

Wadleigh, M ;

DeAngelo, DJ ;

Griffin, JD ;

Stone, RM .

BLOOD, 2005, 105 (01) :22-30

← 1 →